Brought to you by 
Threshold out-licenses TH302 to Merck Serono; Phase III trials fail and deal ends
11 Feb 2022
Executive Summary
Threshold Pharmaceuticals Inc. (cancer drug development) has granted Merck KGAA’s Merck Serono SA division rights to co-develop and exclusively sell globally its TH302, a hypoxia-targeted compound in Phase III trials for soft tissue sarcoma, and in additional studies for other cancers. Threshold retains an option to co-promote in the US, giving it the chance to receive 50% of the profits in that territory.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Threshold out-licenses TH302 to Merck Serono; Phase III trials fail and deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice